AbbVie week: BOTOX oral pain results post; new CLL, myeloma, ABBV-859 trials filed

This week's AbbVie-related clinical trial registry activity centers on one completed study with posted results and four newly registered or recruiting trials across oncology, hematology, and aesthetics.

• A completed phase 2 trial (NCT03848143) tested intraoral onabotulinum toxin A (BOTOX), sponsored by Isabel Moreno Hay with AbbVie as collaborator, in 8 participants (actual)¹ with continuous dentoalveolar neuropathic pain. Posted results showed a mean change in pain intensity of 3.91 (spread .86) at the 3 month follow-up and 3.33 (spread 3.51) at the 6 month follow-up, with 0 of 8 participants experiencing serious adverse events.¹
• AbbVie is sponsoring a phase 3 trial (NCT07728188) of etentamig plus pomalidomide versus standard therapies in relapsed or refractory multiple myeloma, not yet recruiting, with approximately 520 participants enrolled at approximately 200 sites worldwide.²
• AbbVie is sponsoring a first-in-human phase 1 trial (NCT07736638) of ABBV-859 in healthy adults, now recruiting, testing single ascending doses across eight dose groups (Groups 1 through 8), each receiving either ABBV-859 or placebo.³
• AbbVie is a collaborator on a phase 2 trial (NCT07738887, acronym EVITA) evaluating epcoritamab plus venetoclax plus ibrutinib in previously untreated CLL/SLL patients with TP53 alterations, not yet recruiting, with an estimated enrollment of 44 participants (estimated).⁴
• AbbVie is a collaborator on a phase 2 trial (NCT07734038) of venetoclax plus zanubrutinib in newly diagnosed and previously treated CLL/SLL, now recruiting, with an estimated enrollment of 155 participants (estimated).⁵
• AbbVie is sponsoring a phase 2 trial (NCT07730554) of AGN-151586 injections for moderate to severe forehead lines, now recruiting, with an estimated enrollment of 80 participants (estimated).⁶